JPT/PepMix™ Human (Prostatespecific antigen PSA)/PMPSA/

PepMix™Human(Prostate-specificantigenPSA)

ProductCode:PM-PSA

Poolof63peptidesderivedfromapeptidescan(15merswith11aaoverlap)throughProstate-specificantigen(Swiss-ProtID:P07288)ofHomosapiens(Human)forTcellassays(e.g.ELISPOT).
Amount:1vialcontaining15nmol(appr.25µg)perpeptide
Purity:>70%(HPLC-MS)
DeliveryFormat:Freezedriedinambertypeglassvial
Application(s):T-cellassays,Immunemonitoring,AntigenspecificT-cellstimulation,T-cellexpansion,Cellularimmuneresponse
Indication(s)/Topic(s):Cancer,Prostatecancer
DeliveryTime:4-5days

PepMixes™PeptidePools
Theuseofcompleteprotein-spanningmixturesofoverlappingpeptides(PepMix™)isextremelyefficientforimmunostimulationofT-lymphocytesanddiagnosticapplications.InordertoestablishreliableandvalidatedT-cellassayssuchasELISPOT,appropriatepositiveandnegativecontrolsareessential.Selectionofsuchcontrolshelpstoconfirmproperfunctionalityoftheassayaswellasviabilityofthecellsused.Inaddition,highqualitycontrolsaremostimportanttoestablishstandardizedassayprotocolsinclinicalsetups.Comparedtocommonlyusedcontrolslikephytohemagglutinin(PHA)andconcanavalinA(ConA)thatstimulateT-cellsaswellasothercelltypesorfulllengthantigens,syntheticpeptidepoolsoffertheadvantageofahighbatch-to-batchreproducibility,applicabilityofreliablechemicalandbiochemicalQC/QAmeasuresandshelfstabilitywhenstoredasfreezedriedaliquots.

BenefitsofPepMix™
-EquivalentorbetterstimulationofCD4⁺andCD8⁺T-cellresponsescomparedtowholeproteinantigens
-SimultaneousdetectionofCD4⁺andCD8⁺responsesinasinglesample
-ImprovedresponsesinstoredbloodandPBMcellscomparedtowholeproteinantigens
-Morereliableascontrolthanphytohemagglutinin(PHA)andconcanavalinA(ConA)
-High-batch-to-batchreproducibility
-Reliablechemicalandbiochemicalqualitycontrolandqualityassuranceforpeptidesynthesisandpeptidepoolgeneration
-Prolongedshelfstabilitywhenstoredfreezedried

PepMix™Human(Prostate-specificantigenPSA)

SelectedReferences
"DysfunctionofPSA-specificCD8+TCellsinProstateCancerPatientsCorrelateswithCD38andTim-3Expression"
Jappetal.,CancerImmunolImmunother.(2015)-PMID:26289091
"AnHPV-E6/E7ImmunotherapyPlusPD-1CheckpointInhibitionResultsinTumorRegressionandReductioninPD-L1Expression"
Riceetal.,CancerGeneTherapy(2015)-PMID:26337747
"Survivin-specificCD4+TCellsareDecreasedinPatientswithSurvivin-positiveMyeloma"
Lockeetal.,JImmunotherCancer(2015)-PMID:25992291
"APhaseITrialCombiningDecitabine/dendriticCellVaccineTargetingMAGE-A1,MAGE-A3andNY-ESO-1forChildrenwithRelapsedorTherapy-RefractoryNeuroblastomaandSarcoma"
Krishnadasetal.,CancerImmunolImmunother.(2015)-PMID:26105625
"GuidelinesFortheAutomatedEvaluationofElispotAssays"
Janetzkietal.,NatureProtocols(2015)-PMID:26110715
"PresenceofCirculatingHer-2-reactiveCD8+T-CellsisAssociatedwithLowerFrequenciesofMyeloid-derivedSuppressorCellsandRegulatoryTCells,andBetterSurvivalinElderlyBreastCancerPatients"
KiniBailuretal.,BreastCancerResearch(2015)-PMID:n.a.
"STAT3SignalingContributestotheHighEffectorActivitiesofInterleukin-15-derivedDendriticCells"
Okadaetal.,ImmunolCellBiol.(2015)-PMID:25582338

ApplicationNotes
"DevelopingMulti-HIVAntigenSpecificT-CellsasaComponentofaCureStrategy"
Lametal.(2015)Fulltext
"Peptide-stimulatedExpansionofVirus-specificTcellsForPreventativeTreatmentAfterAllogeneicStemCellTransplantation"
Garyetal.(2015)Fulltext

Testimonials
"Toestablishanovelroleformyeloidderivedsuppressorcells(Pallettetal,Nat.Med.2015)inchronicviralinfection,weutilisedthePepMixCEFPool(extended)aswellasacustomsynthesizedPepMixspanningthecoreregionofHBVgenotypeD.Whereas,theCEFpeptidepoolconsistsof32peptides,eachcorrespondingtoadefinedHLAclassI-restrictedT-cellepitopefromCytomegalo,Epstein-Barr,andInfluenzavirus,thelattercustomPepMixincluded15mericpeptidesoverlappingby10aminoacids.SpecificallythiscompositionenabledustomonitorboththeantiviralCD8+andCD4+TcellresponsesinchronicHBVinfectionandthenon-antigenspecificTcellsthatareknowntomediateimmunopathologyintheliver.OurentireexperiencewithJPT,fromordering/deliverytouseinthelabwasexcellent.Notonlywerethereagentsabletoperformreliablyandconsistentlyinvitrofrombatchtobatch,thecustomerandtechnicalsupportprovidedwascontinuallyavailableandefficientwhenneeded.JPTwillremainour"go-to"companyforpurchasingpeptides."
Dr.LauraJPallett,InfectionandImmunity,UniversityCollegeLondon,UK